Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2027

Conditions
Heart FailureCardiac Resynchronization Therapy
Interventions
DEVICE

Implantation of the Axone 4LV Lead

Implantation of the Axone 4LV Lead

Trial Locations (21)

Unknown

Kepler Universitätsklinikum, Linz

CH Annecy Genevois, Annecy

CHRU Hopital Trousseau, Chambray-lès-Tours

CHU de Clermont-Ferrand, Clermont-Ferrand

CHU Grenoble, Grenoble

CHRU de Lille - Hôpital Cardiologique, Lille

CHU Pontchaillou, Rennes

CHU de Rouen, Rouen

CHU Toulouse, Toulouse

Universitätsklinikum Hamburg Eppendorf, Hamburg

Universitätsklinikum Heidelberg, Heidelberg

Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel

ASST Spedali Civili di Brescia, Brescia

Ospedale Pellegrini, Naples

Ospedale Policlinico Federico II, Naples

Isala Klinieken, Zwolle

Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria, Lisbon

Centro Hospitalar Universitário do Porto, Porto

Hospital Universitario General de Alicante, Alicante

Hospital Universitario La Fe, Valencia

Hospital Álvaro Cunqueiro, Vigo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MicroPort CRM

INDUSTRY

NCT04463641 - Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy | Biotech Hunter | Biotech Hunter